Sensor Systems, Devices, and Methods for Continuous Glucose Monitoring
Medtronic, headquartered in Minneapolis, MN, is developing sensor systems that utilize electrochemical impedance spectroscopy (EIS) for continuous glucose monitoring. Medtronic recently secured expanded approval from the FDA for its Pipeline Flex embolization device, which allows the company to treat patients with small or medium, wide-necked brain aneurysms in the territory from the petrous to the terminus of the internal carotid artery.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…